An Israeli company specializing in medical devices has developed an innovative technology for freezing cancerous tumors in a minimally invasive manner with use of liquid nitrogen. Advantages over those on the market include its greater efficiency, speed and compactness as well as plenty of excellences resulted from its save, efficient and cost-effective procedure of performance. The company is looking for distribution services, commercial agency and licensing agreements.
The Israeli company is engaged in the development of medical equipment in the field of ablation (any treatment aimed at the destruction / removal of diseased tissue in the body) for the treatment of various cancers, with an emphasis on breast cancer.
Their proprietary therapy systems provide minimally invasive an office-based definitive treatment for symptomatic tumors in various organs.
The company sells its products in the U.S.A. (both directly and through distributors) by its subsidiary company with its office in the U.S.A. Among their US clients there are breast centers in reputable institutions as well as private clinics operated by breast surgeons and radiologists. In other geographies, the company uses specialized distributors that provide clinical and technical sales support in Asia and Europe.
Thanks to its unique and innovative technology, the company participates in several clinical studies for treatment of other indications such as lung cancer, kidney cancer and breast cancer.
With the global trend of taking procedures from the operating room to the office environment and decreasing their costs, the company’s innovation brings the future.
The company is offering to the market an innovative developed procedure, which is an attractive alternative to the current standard treatment of open surgical excision. Cryoablation is a minimally-invasive treatment that uses extreme cold to freeze and accurately destroy diseased tissue within the tumor zone. Cryoablation exists more than 2 decades and has been successfully used in various applications based on slow, gas-based technology. The procedure is done under ultrasound or CT imaging to guide a small probe (thin hollow needle) into the tumor. The company uses liquid-nitrogen-based technology, which is more compact, faster and more efficient. The system uses extremely cold temperatures to destroy (ablate) the targeted tumor in situ.
The cryoablation procedure is a safe and effective treatment option that can be performed in short time in comfort of a doctor’s office. The company proprietary system provides minimally invasive, in-office definitive treatment for breast tumors, both benign and breast cancer.
The company's product is a machine (a system) and a disposable (probe / needle), through which the doctor freezes tumored tissue with the cold to minus (-!) 170 degrees Celsius. With the help of the system and the needle, injection of liquid nitrogen freezes tumoured tissue while maintaining healthy tissues in the area. The ablated tumor becomes necrotic and as such, shrinks and absorbed by the immune system.
The procedure is performed by one physician in the office under local anesthesia. It can be completed in 5-15 minutes with no pain, no scar, but superior cosmetic results. It requires short recovery time and is promising treatment for small breast cancer tumors.
The device has FDA and CE standard.
The target business partners are distributors with existing strong connections with breast surgeons, gynecologists, breast radiologists and existing close connections to interventional oncologists.
The company works with distributors in EU and is examining whether to locate US distributors. The company is in contact with two distributors in Asia. In fact, they are looking for distributors who will carry out the licensing process themselves. The company is going to provide them training (and they will train the hospital staff). The Company shall be responsible for the maintenance of the machine. Potential partners are
distributors of medical devices, breast surgery and radiology oncology. The company is interested in distribution services, commercial agency and licensing agreements.
- Specific area of activity of the partner: -TYPE - business, trade
-ACTIVITY - distributor / agent / representative (companies) with experience/ knowledge in medical devices / breast cancer / interventional radiology, breast surgery aspects and contacts in medical community, hospitals and clinics
-ROLE - to find local customers, to supply the locally required service including licensing procedures.
Innovative liquid-nitrogen-based technology has the following advantages:
1.It is more compact, faster and more efficient, than others of the same purpose.
2.Its performance procedure is a safe and effective treatment option that is characterized by:
a) performance by one physician as an office procedure, which can be completed in 5-15 minutes,
b) short recovery time - the process activates the patient's immune system, thereby contributing to the healing of the disease,
c) local anesthesia only - suitable for patients who cannot enter full anesthesia
d) saving the costs of an anesthesiologist and an operating room,
e) very low percentage of recurrence rates - 1-1.3% as compared to 5% at competitors in the field.
f) replacement of the surgical operation,
g) lower costs - use of one needle instead of 3 by competitors,
h) no pain - a more efficient and less painful process than heat ablation,
i) no scar - superior cosmetic results.
Already on the market
Patents granted - The company has active patents in the US, Europe, Japan and China.
Clasificado como: Medicine and Health \ Physical and Exact Sciences \ Servicios financieros, legales, profesionales y otros
Seleccione una de las siguientes opciones para interesarse por esta oportunidad: